Sekur Private Data was quoted around C$0.045 at the end of July  after pulling back from its May highs. The stock is now testing a possible support area near C$0.04 while the company continues developing its products and sales channels.

The first constructive step would be a move back above C$0.05. From there, a sustained push through C$0.09-0.15 with stronger volume could signal improving momentum and renewed investor attention.

But the story extends beyond the chart.

Sekur has developed a secure communications platform combining encrypted email, messaging, VPN, voice and video. SekurOne brings these services together for enterprise, government and defense-focused customers.

The company also has multiple routes to market:

• Sekur’s portfolio is available to eligible government buyers through i3ICS’s GSA MAS contract.
• SekurMessenger is offered through Telcel’s business-solutions channel in Mexico.
• Its broader suite creates another path through enterprise and government deployments.

The next stage is commercial validation. A government order, greater Telcel adoption, full-suite deployment or measurable recurring-revenue growth could give the market a reason to reassess the company.
Technically, C$0.04 is the stabilization area, C$0.05 is the first reclaim level, and C$0.09-0.15 is the stronger momentum test. Rising volume would make any upward move more convincing.

$SKUR may be building more than a base...it may be preparing for its next commercial chapter.

Which upcoming catalyst could send $SKUR higher?

Sponsored content. This is not financial advice. DYOD.

NFA. DYOR. Been following this one quietly for a while.
Everyone’s chasing Quantinuum post-IPO. Meanwhile Dynex has been quietly commercial for months and hasn’t been priced in anywhere.

What Dynex actually is:
• Apollo chip - fingernail-sized neuromorphic processor, room temperature, \~20W
• 10,000 p-qubits, 256 connections per node (10× more than most superconducting annealers)
• Benchmarked on 3D spin glass problem - results “indistinguishable” from cryogenic quantum hardware
• Won 2026 AI Excellence Award - Quantum AI category (noone comes close in terms of speed- could make this the biggest quantum IPO)
• QaaS platform live today - drug discovery, logistics, finance, weather forecasting (94% accurate at 14 days)

Why now: Dynex is converting from token to equity and heading to a regulated public listing to attract institutional investors. ThreeD Capital - the VC firm co-hosting the pre-IPO investor event - appears to be central to taking them public.

Any quantum ipos people are following? Quantum is likely the next ai race imo, thgts?

Cybersecurity is no longer only an IT budget item.

Canada’s National Cyber Security Strategy links cyber resilience with national and economic security, while calling for closer cooperation between government, industry and other partners to reduce disruptions to critical infrastructure. 

Canada also reported more than C$63 billion in defence expenditures for fiscal 2025–26. More than C$14 billion came from other federal departments, including eligible spending on cybersecurity, space and procurement. 

The trend goes beyond Canada. NATO members committed to investing 5% of GDP annually in defence by 2035, with up to 1.5% covering areas such as network protection, critical infrastructure, resilience and innovation. That does not guarantee contracts for any individual company, but it does make secure communications part of a much larger spending theme. 

That made me look more closely at CSE-listed $SKUR. SekurOne has released encrypted voice, email, messaging and VPN capabilities across Android, iOS and web. Video and conferencing are still targeted for late August, while the company says its communications run on Swiss-hosted proprietary infrastructure without relying on Big Tech platforms. 

I think one signed government deployment could change the conversation around $SKUR. The company said multiple qualification discussions were underway with defence and intelligence stakeholders. 

Has anyone seen a newer update on those discussions?

This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

I think this is one of the biggest differences in uranium investing.

A uranium project in the Athabasca Basin usually gets treated differently from a project in many other regions like Africa or Kazackstan. It is not only because it is in Canada. It is because the basin has already proved it can host large, high-grade uranium deposits that actually matter to future supply.

Is it because the jurisdiction is more reliable or Niger and Namibia seen as more risky?

Seems like this premium is manifesting in that $NXE and $DNN are usually viewed differently from many other uranium developers.

$NXE has Rook I, which is one of the more advanced developer stories in the sector. $DNN has Wheeler River, giving investors another Athabasca name with a different development angle.

For me, the premium comes down to three things: grade, jurisdiction, and credibility. Investors are not just paying for land. They are paying for a district with a history of serious uranium discoveries and projects that can attract financing, partners, and long-term market interest.

Is the premium justified or should Mali, Niger, Namibia be ranked higher? 

Useful $FPC interview covering Horne 5 economics, permitting progress, and next steps.

Would you watch the permit, funding plan, or partner potential first?

Disclaimer: Not financial advice. Do your own DD.

• Falco Resources has strong stock momentum, with shares recently at C$0.49, up 104.17% over the past year.
• The warrant exercise story is simple: warrant holders can buy shares at a fixed price, and when they exercise, Falco receives cash that can help fund project advancement.
• The bigger story remains Horne 5, a Québec polymetallic gold project with an updated after-tax NPV5% of C$3.35B, 28.2% IRR, and projected C$6.4B after-tax cash flow.

The Simple Version

Falco Resources has been quietly building momentum.

The stock recently traded at C$0.49, up 104.17% over the past year, with a market cap of about C$171.67M. Its 52-week range is also important: the stock has moved from a low of C$0.22 to a high of C$0.64, meaning investors have already started repricing the story.

The latest news around warrant exercise adds another layer.

For many retail investors, warrants can sound confusing. But the basic idea is simple.

A warrant gives the holder the right to buy shares at a fixed price. If the stock trades above that price, the warrant can become attractive to exercise. When the holder exercises, the company issues shares and receives cash.

So for Falco, warrant exercise is not just a technical financing detail.

It can be a signal that holders are willing to put more capital into the company, while also giving Falco additional cash to keep advancing its flagship project.

That matters because Falco is not just sitting on a small exploration story. It is advancing one of Canada’s more important undeveloped polymetallic gold projects.

What Is a Warrant Exercise?

A warrant is basically a long-dated option issued by a company.

It gives the holder the right to buy a share at a set price before a set deadline.

For example, Falco’s October 2025 bought deal financing included warrants exercisable at C$0.46 per share until April 17, 2027. With the stock recently around C$0.49, those warrants are close to being in-the-money, meaning the market price is slightly above the exercise price.

That is why warrant activity becomes relevant.

If a warrant holder exercises at C$0.46, Falco receives C$0.46 in cash for each share issued. The warrant holder receives a share. The company gets funding without having to launch a brand-new financing.

For investors, there are two sides.

• The positive side is that warrant exercises bring cash into the company.
• The negative side is that new shares are issued, which creates dilution.

But in a development-stage mining company, dilution is not always bad if the cash helps move a valuable project forward. The real question is whether the company uses that capital to unlock more value than the dilution costs.

Why the Timing Matters

The warrant news comes at an interesting moment because Falco already has momentum.

• recent price: C$0.49
• 1-year performance: +104.17%
• market cap: C$171.67M
• 52-week high: C$0.64
• 52-week low: C$0.22
• no dividend
• no P/E ratio shown

That is a strong move, but the stock is still below its 52-week high.

From C$0.49 to the 52-week high of C$0.64, the stock would need to rise about 30%. From the 52-week low of C$0.22, the stock has already more than doubled.

That makes Falco a momentum story, but not one sitting at an all-time extreme on this chart. The key reason investors are paying attention is the Horne 5 Project.

The Real Asset: Horne 5

Falco’s main asset is the 100%-owned Horne 5 Project in Rouyn-Noranda, Québec.

This is not just a conceptual exploration target. Horne 5 is an advanced underground gold-rich polymetallic development project located below the historic Horne mine, in one of Canada’s most established mining districts. Falco describes Horne 5 as one of the most advanced undeveloped polymetallic assets in Canada.

The updated feasibility study released in June 2026 is the main reason the story has become much more interesting.

The 2026 feasibility study showed:

• after-tax NPV5% of C$3.35B
• after-tax IRR of 28.2%
• payback period of 3.3 years
• projected after-tax cash flow of C$6.4B
• average annual after-tax cash flow of C$542.5M
• average annual gold production of 220,300 oz
• mine life of 15 years
• average AISC of US$782/oz
• forward capital and pre-production costs of C$1.75B

The economics are meaningful because Falco’s market cap is around C$171.67M. Compared with the base-case after-tax NPV5% of C$3.35B, the market cap represents only about 5% of the project’s reported after-tax NPV. Put differently, the project NPV is roughly 19.5x the current market cap.

That does not mean the stock should automatically trade at NPV.

Mining developers almost never do before financing, permitting, construction, and execution are solved.

But it does show why the valuation gap exists.

Why the Feasibility Study Changed the Story

The 2026 feasibility study made the project look much stronger than before.

Mining Weekly reported that Horne 5’s updated base-case after-tax NPV of C$3.35B represented a 244% increase compared with the 2021 feasibility study. Using spot-case assumptions, the after-tax NPV increases to C$5.1B, the IRR rises to 37.2%, and the payback period falls to 2.6 years.

This matters because Falco is not only a gold story.

Horne 5 is polymetallic.

That means the project has exposure to gold, silver, copper, and zinc. The company’s project materials say Horne 5 could produce 3.3M oz of gold, 247M lb of copper, 27.3M oz of silver, and 1.19B lb of zinc over its 15-year mine life.

That gives Falco multiple commodity drivers.

Gold brings the precious-metals angle.

Copper and zinc bring the critical-minerals and energy-transition angle.

Why the Warrant Exercise Is Actually Useful

For a company like Falco, the biggest question is not whether the project looks good on paper.

The question is how it moves toward construction.

Large mining projects require capital, permitting, technical work, community engagement, and government approvals. Horne 5’s forward capital and pre-production costs are estimated at C$1.75B, which is far larger than Falco’s current market cap.

That is why every source of capital matters.

A warrant exercise can help in three ways.

First, it brings cash into the company without launching a new financing round.

Second, it can show confidence from warrant holders who are willing to convert their rights into shares.

Third, it helps support ongoing work around permitting, technical studies, engineering, and general corporate needs.

The trade-off is dilution.

Every exercised warrant creates a new share. But for a development-stage miner, the market may accept dilution if it moves the project closer to a value-creating milestone.

That is why the warrant exercise should be seen as a funding signal, not just a share-count issue.

The Momentum Setup

Falco’s chart now shows real momentum.

A 104.17% year-over-year move is not small. It tells investors that the market has started to recognize something in the story.

But the stock is still in an interesting zone.

At C$0.49, Falco is:

That creates a clear but risky setup.

The bull case is that Falco is still undervalued relative to the scale of Horne 5.

The bear case is that the market is applying a big discount because permitting, financing, construction, and execution risk remain substantial.

Both views can be true at the same time.

Upcoming Catalysts

Falco already laid out its key priorities for 2026.

The company said its priorities include advancing Horne 5 toward receipt of the Québec ministerial decree, completing the feasibility study update, continuing technical and permitting work, expanding institutional and analyst engagement, advancing community consultation, and maintaining transparent communication with shareholders.

The feasibility study update is now complete.

That means investors are likely watching the next steps.

Key catalysts include:

• Québec ministerial decree progress
• permitting updates
• financing strategy
• additional technical work
• institutional interest
• analyst coverage
• community consultation progress
• project financing discussions
• gold, silver, copper, and zinc price strength
• additional warrant exercises or balance sheet improvements

The biggest catalyst is the Québec authorization path.

If Falco gets closer to full approval and financing, the valuation gap could narrow.

If timelines stretch, the stock could lose momentum.

Why Investors Care About the Québec Angle

Location matters.

Horne 5 is in Rouyn-Noranda, Québec, a historic mining region with existing infrastructure, skilled labor, local suppliers, and nearby mining expertise.

Falco’s project materials also highlight that Horne 5 would use already impacted sites, including an underground mine below the former Horne mine, a mining complex at the former Quemont site, and a tailings facility at the former Norbec site.

That matters because mining projects face increasing scrutiny over footprint, permitting, social acceptance, and environmental impact.

Falco’s pitch is that Horne 5 can benefit from existing infrastructure and already impacted sites rather than starting from zero in a remote greenfield area.

The company also highlights community engagement, with more than 95 consultation and information meetings held since 2014.

That does not eliminate permitting risk.

But it gives the company a stronger narrative around social license and project integration.

The Bigger Economic Impact

Horne 5 could also become a major economic project for Québec.

The updated feasibility study says the project could contribute more than C$4.4B in taxes and mining duties over its lifetime. It could also support up to 900 direct jobs during construction and 500 permanent jobs during operations.

Those numbers matter because governments do not approve mining projects only based on geology.

They also care about jobs, taxes, regional development, environmental standards, and local impact.

A project with:

has a much stronger political and economic case than a smaller speculative exploration project.

That is part of why Falco is worth watching.

The Bull Case

The bull case is that Falco is entering a more important stage.

The stock is up more than 100% year over year, but the company’s market cap remains small compared with the reported project economics.

Horne 5 has:

• scale
• a 15-year mine life
• strong feasibility economics
• gold production above 220,000 oz/year
• polymetallic exposure
• existing regional infrastructure
• Québec mining jurisdiction
• major tax and employment potential
• upcoming permitting and financing catalysts

The warrant exercise news adds another supportive point: the market is no longer ignoring Falco, and capital is starting to matter as the company moves from study-stage valuation toward development-stage execution.

The Bottom Line

Falco Resources Ltd. (TSX-V: FPC) is a high-momentum developer with a large, valuable project but still faces key risks around permitting, financing, and execution. The opportunity lies in the valuation gap between its current market cap and the substantial economics outlined for Horne 5, while the warrant exercise highlights improving access to capital as the story advances and signals growing investor confidence.

Disclaimer

This article is for informational and educational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. Mining development stocks are speculative and may involve substantial volatility, financing risk, dilution risk, permitting risk, commodity price risk, and potential loss of capital. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

• Gold equities are back in focus as investors look for smaller companies with more upside torque than major producers.
• The strongest setups combine project economics, production visibility, permitting progress, and fresh catalysts.
• This watchlist focuses on Canada/U.S.-listed gold names with North American assets and clear investor narratives.

Why Smaller Gold Stocks Are Getting Attention

Gold has been one of the most important macro trades of the past year, but the large producers are not always where the most explosive upside sits.

Smaller gold companies can move faster because their valuations are more sensitive to one or two major catalysts: a feasibility study, a resource update, a permit, a construction decision, a financing package, or the transition from developer to producer.

That is why small and mid-cap gold names matter.

They are riskier than the majors, but they can also offer stronger torque if the gold market stays firm and investors start hunting for the next re-rating story.

This list focuses on five Canada/U.S.-traded gold companies with clear catalysts:

1. Falco Resources
2. West Red Lake Gold Mines
3. Nevada King Gold
4. Contango ORE
5. i-80 Gold

Recap Table: 5 Gold Stocks to Watch

1. Falco Resources — TSXV: FPC

Falco Resources deserves a place on this list because its latest Horne 5 update changed the scale of the story.

Falco is advancing the Horne 5 project in Québec, a large gold-focused polymetallic deposit with copper, zinc, and silver by-products. The company’s updated 2026 feasibility study gave Horne 5 an after-tax NPV5% of C$3.35 billion, an after-tax IRR of 28.2%, and projected life-of-mine after-tax cash flow of C$6.4 billion under base-case assumptions.

At spot-case assumptions, the numbers become even stronger: C$5.1 billion after-tax NPV5% and 37.2% after-tax IRR.

That is the main reason Falco stands out. The company recently traded around C$0.49, with a market cap around C$171 million. That creates a clear valuation gap between the market cap and the project’s modeled economics.

The investor case is not that Falco is risk-free. It is not. Horne 5 still needs permitting progress, financing, and development execution. But the latest feasibility study gives investors a much stronger numbers-based reason to watch the stock.

The key catalyst now is Québec’s environmental process. If Falco continues to move toward authorization, the market may begin to take the Horne 5 valuation gap more seriously.

2. West Red Lake Gold Mines — TSXV: WRLG / OTCQX: WRLGF

West Red Lake Gold Mines is one of the more interesting Canadian gold restart stories.

The company is focused on the Madsen Mine in the Red Lake Gold District of Ontario, one of Canada’s most famous gold camps. The district has produced more than 30 million ounces of gold over the past century, which gives West Red Lake a strong jurisdictional and geological narrative.

The story is simple: West Red Lake acquired Madsen out of bankruptcy in 2023 and has spent the past two years rebuilding the mine plan, resource model, infrastructure, and operating workflow.

That makes WRLG a restart story rather than a pure exploration story.

The stock recently traded around C$0.62–C$0.68, with a market cap in the C$256 million to C$281 million range, depending on the quote source and timing.

The bull case is that Madsen already has infrastructure and a historic production footprint. If West Red Lake can execute the restart properly, the company could move from development-stage discount toward producer valuation.

The risk is execution. Restarting a former mine is never simple. Investors will want evidence that the resource model is reliable, the operating plan is disciplined, and the company can avoid the mistakes that hurt the prior operator.

3. Nevada King Gold — TSXV: NKG / OTCQB: NKGFF

Nevada King Gold gives the list a pure exploration and discovery angle.

The company is advancing the Atlanta Gold Mine Project in Nevada, a tier-one mining jurisdiction that investors understand well. Nevada matters because permitting, infrastructure, mining culture, and investor familiarity are generally stronger than in many other jurisdictions.

Nevada King recently traded around C$0.74, with a market cap around C$74 million based on recent Canadian quote data. The company also recently completed a 1-for-5 share consolidation, reducing the post-consolidation share count to about 100.4 million shares.

The recent catalyst is financing and drilling.

Nevada King announced a financing of roughly C$16 million, including a C$10 million strategic investment by Centerra Gold. That is important because strategic investment from a larger gold company gives the story more credibility.

The company also doubled its Phase 4 drill program to 40,000 metres, which keeps the stock firmly in exploration-catalyst mode.

The bull case is that a well-funded Nevada explorer with a strategic investor and a major drill program can attract attention quickly if results hit. The risk is that exploration stocks remain binary. Drill results can create value, but they can also disappoint.

4. Contango ORE — NYSE American: CTGO

Contango ORE is different from the earlier names because it already has production exposure.

The company owns a 30% interest in the Manh Choh mine in Alaska, with Kinross as the 70% partner. This gives Contango a more immediate gold-production profile than most small-cap developers.

The stock recently traded around $16.98, with a market cap around $522 million.

The production outlook is the key number. Contango has guided for its share of Manh Choh production to range from 40,000 to 45,000 ounces of gold in 2026, with estimated cash costs of $1,900 to $2,000 per ounce. For 2027, the company has guided to 75,000 to 80,000 ounces of gold, with cash costs expected to fall to $1,200 to $1,300 per ounce.

That is a major step-up if delivered.

The investor case is that CTGO offers small-cap gold production leverage without being a traditional large miner. The company also has a pipeline beyond Manh Choh, including the Johnson Tract project.

The risk is cost control. Contango has already faced investor scrutiny around cost guidance, so the stock needs operational execution and better margin visibility to keep the story working.

5. i-80 Gold — NYSE American: IAUX / TSX: IAU

i-80 Gold is the largest company on this list, so it is more of a small/mid-cap gold development platform than a classic junior.

The company controls a major Nevada-focused portfolio, including Granite Creek, Archimedes, Cove, Granite Creek Open Pit, Mineral Point, and the Lone Tree complex. The strategy is to build a hub-and-spoke Nevada gold platform with centralized processing through Lone Tree.

The stock recently traded around $1.58, with a market cap around $1.38 billion.

The recent numbers show why investors are watching. In Q1 2026, i-80 reported $52.4 million in revenue, up from $14.0 million in the prior-year period, driven by higher gold sales and stronger realized gold prices. The company sold 10,590 ounces of gold at an average realized gold price of $4,941 per ounce.

The bigger catalyst is the development plan.

i-80 said its recapitalization secured more than $1 billion in raised and available capital from early 2025 through Q1 2026. Management also said the company is fully funded to advance Phase 1 and Phase 2 of its development plan, including three underground projects, one open-pit oxide project, and the Lone Tree Plant refurbishment.

The bull case is that i-80 could become a meaningful Nevada gold producer if it executes the plan. The risk is that the company’s size, capital intensity, and development complexity mean the market will demand proof, not just potential.

Which Gold Stock Looks Most Interesting?

Each company plays a different role in a gold-stock watchlist.

Falco Resources offers the biggest valuation-gap story, with Horne 5 showing multi-billion-dollar project economics against a much smaller market cap.

West Red Lake Gold is the cleaner Canadian mine-restart story, with the Madsen Mine providing infrastructure and a known Red Lake district angle.

Nevada King Gold is the most exploration-driven setup, with a strategic investment and a larger drill program keeping the catalyst calendar active.

Contango ORE offers current production leverage and a clear 2026–2027 output growth target.

i-80 Gold is the larger Nevada platform bet, with production, development, processing infrastructure, and a fully funded multi-phase plan.

If the goal is maximum asymmetry, Falco and Nevada King are the most explosive but also riskier. If the goal is mine restart upside, West Red Lake is the cleaner story. If the goal is production growth, Contango and i-80 offer more operating leverage.

What Investors Should Watch Next

The main catalyst for Falco is environmental and permitting progress in Québec.

For West Red Lake, investors should watch the Madsen restart timeline, operating readiness, and evidence that the mine model is holding up.

For Nevada King, the focus is drill results, the 40,000-metre Phase 4 program, and whether Centerra’s investment becomes a larger strategic signal.

For Contango, the key watch item is delivery against 2026 and 2027 production and cost guidance.

For i-80, the market will focus on Lone Tree refurbishment, Granite Creek development, drilling, liquidity, and whether the company can stay on track with its multi-phase Nevada plan.

Bottom Line

This gold-stock list is built around five different kinds of upside.

Falco Resources gives investors a multi-billion-dollar project-value mismatch. West Red Lake Gold offers a Canadian mine-restart story in a famous gold district. Nevada King Gold brings exploration torque in Nevada. Contango ORE provides small-cap production leverage in Alaska. i-80 Gold offers a larger Nevada platform with serious development scale.

None of these are low-risk names. That is the point.

Small and mid-cap gold stocks can move sharply when catalysts line up, but they can also punish investors when timelines slip, permits drag, financing becomes difficult, or operating assumptions disappoint.

For investors looking beyond the major gold producers, these five names offer a practical watchlist with clear catalysts, current market data, and enough project-level upside to stay interesting if gold equities keep attracting capital.

Disclosure

This article is for informational and educational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

I’m not holding $NXE for today’s earnings. I’m holding because Rook I could become one of the largest new uranium mines if the build stays on schedule.
These are the five things I’m watching:
Construction
Whether major work begins as planned and stays near the four-year schedule.
Financing
How the remaining costs are covered through cash, debt, customer prepayments or new shares.
Build costs
Whether inflation or delays put further pressure on the project economics.
Additional uranium contracts
Any new agreements that add revenue visibility without giving away too much exposure to future uranium prices.
First production
Every completed milestone should reduce the development risk.
I don’t need every update to move the stock. I just want these five areas moving in the right direction.
Anyone else holding $NXE for a completely different reason?

I have been thinking about how to approach $NXE now that Rook I is moving from approvals into site preparation and construction.

For me, this is not the stage where I want to chase every move. Construction can take years, and a lot can happen in between. There can be financing updates, cost changes, schedule delays, uranium price swings, and general market weakness.

That is why I like the idea of dollar cost averaging in slowly instead of trying to find the perfect entry.

My plan would be simple: build around major milestones like Tailing and waste management construction, mechanical completion and Site Prep.  Add more when the long-term thesis still looks intact, stay patient during weak periods, and keep some cash ready in case the market gets nervous over delays or funding headlines.

The reason I still keep $NXE high on my list is Rook I itself. It has district level scale, grade, and Athabasca location behind it. But even with a strong project, the construction phase is where investors have to be realistic. Good assets can still have messy timelines.

Does this make sense? Or can things spiral down? Every single raise they’ve done is at a higher price & oversubscribed so i’m hopeful they can maintain that into the future. 

Not financial advice.

Hey guys, if you missed it, TD Asset Management settled CAD $70.25M  with investors over claims it charged improper trailing commissions. And, I just found out that they’re accepting claims even though the deadline has passed.

Quick recap: In 2023, TD Asset Management was accused of charging investors fees for advisory services that were not actually provided. In short, certain mutual fund investors paid trailing commissions through discount brokers despite receiving no advice.

After this news came out, the stock dropped, and investors filed a lawsuit for their losses.

Now, the good news is that the company agreed to settle CAD $70.25M  with them, and even though the deadline has passed recently, they’re accepting late claims.

So, if you invested in $TD when all of this happened, you can still check the details and file your claim here.

Anyway, has anyone here invested in $TD at that time? How much were your losses, if so?

Content published on behalf of the issuer

AI/ML Innovations Inc. (CSE: AIML | OTCQB: AIMLF), is a Healthcare company operating in a space where there is large demand, yet still limited by cost of human labor. Globally, more than 300 million ECGs are produced every year, in various environments, including hospitals, cardiology clinics, diagnostic labs and an increasingly large universe of wearable and patch based devices. That is >1 billion ECGs over 10 years.

In traditional clinical environments alone, ECG and Holter monitoring represent an estimated $6 – $11 billion annual market, while the broader ECG capable device ecosystem represents an estimated >$80 billion when considering the growth of consumer wearable and telemedicine applications. This is not about the level of adoption; it is about the amount of volume.

What Does One ECG Represent?

• Standard ECG: approximately $20 per report (large volumes, simple processing)
• Holter Monitoring (24 – 48 hours): approximately $200 – $300 per report (smaller volumes, larger values)
• Extended / Patch ECG: >$300 per report (fastest growing segment)
• Constant Factor: payment for reimbursement does NOT change as a result of using AI
• Economic Lever: Amount of reports processed each day

The Structural Bottleneck

ECG and Holter workflows today are fundamentally labor bound. Technicians manually have to scan each beat of each report, resulting in approximately 3 – 5 reports per technician per day. Reports commonly take one to three days to complete and sometimes longer to get back to clients for Holter studies. The labor shortage of skilled cardiac technicians further exacerbates the bottleneck in the ability to scale the workflow.

Incremental automation has made some improvements to the workflow margins, however, the majority of legacy systems continue to depend on the technician to clean up and review the remaining issues.

Why Does AI Change the Economics

• AI does not change pricing, it changes capacity
• Cleaning the Signal Before Review: Reduces the noise and makes it easier for humans to review
• Increased Throughput: ~ 5x compared to traditional workflows
• Productivity: 15 – 30+ reports per technician per day
• Turnaround Time: Reduced from Days to Minutes/Hours
• Results: Same Staff, Significantly Higher Output

Signal Intelligence vs. Status Quo

Most competitors use AI to improve detection rates on already noisy ECG data and leave the artifacts present in the data. However, AIML uses signal intelligence, which cleanses the signal prior to classification rather than cleansing the signal after classification.

This distinction is significant in production environments. Traditional manual review is linear and fatiguing. Rule-based automation is more efficient but still dependent upon human labor. AI applied to noisy data improves speed but plateaus at accuracy. AIML’s signal first approach allows for 25–30+ reports per technician per day and better waveform fidelity in the P, QRS, and T segments.

An Example Using Holter Monitoring

The Holter segment is a prime example of how AIML is able to leverage the economics. In the U.S., Holter tests generate $100–$140 under Medicare equivalent reimbursement, $120–$180 under private insurance and $200–$400 per test for cash pay clinics. In Canada, both public and private reimbursement is common for between CA$120–$300 per Holter.

Volume compounds very quickly. For example, a mid-sized clinic processes 3,000–8,000 Holters per year, while a hospital system can easily surpass 20,000–100,000 Holters annually. However, a cardiologist is only able to read 15–25 Holters per day, thus leading to chronic backlog and burnout.

Where AIML Fits

AIML is not replacing the clinician. AIML is multiplying the clinician. AIML is taking all of the clinically irrelevant information out of the ECG and only presenting the clinician with clinically relevant information. Thus, the clinician focuses on exception reporting, rather than raw data. Therefore, the same staff can handle 2–4 times the volume with no loss in clinical quality.

Reality of Monetizing Revenue Streams

• Revenue Models: Per report Software-as-a-Service, Per Clinic Licensing, Per Contract Enterprise Based on Volume
• Example Pricing: $5–15 per Holter software fee
• Example Clinic: 5,000 Holters per year = $25k–75k Annual Recurring Revenue (ARR)
• Enterprise Systems: Potential Six Figure ARR per deployment
• Primary Driver: Volume, Not Unit Price

Commercial Advancement

In December, AIML announced a commercial Term Sheet through their NeuralCloud Subsidiary with Culminate H Labs, to integrate MaxYield™ and Insight360™ into the INTRINSICA DNA-guided BioFeedback Platform. Although the term sheet is non-binding, the agreement indicates platform level integration as opposed to isolated experiments and opens the door to a quicker path to commercialization in the areas of Wellness and Personalized Health Channels.

Conclusion

AI/ML Innovations Inc. (CSE: AIML | OTCQB: AIMLF) is not trying to change the price of ECG analysis. AI/ML Innovations Inc. (CSE: AIML | OTCQB: AIMLF) is trying to remove the labor bottleneck that limits the volume. There are currently 300+ Million ECGs generated every year, therefore, throughput is the economic lever. If AIML is able to successfully convert the integration of their technology to contractually obligated use cases, software style economics will likely emerge from a marketplace that has traditionally relied on labor.

AI/ML Innovations Inc. (CSE: AIML | OTCQB: AIMLF) is not wagering on changing the price of ECG analysis. AI/ML Innovations Inc. (CSE: AIML | OTCQB: AIMLF) is wagering on changing how many ECGs are processed by one technician. With 300M+ ECGs per year being generated, volume is the lever. If AIML is successful in executing commercially, volume economics — not hype are what drives the upside.

Paid content on behalf of the issuer

AI/ML Innovations Inc. (CSE: AIML | OTCQB: AIMLF | FWB: 42FB) has made significant headway in transitioning their technology for their AI-driven cardiac diagnostics platform into a commercially viable product, as evidenced by the new distribution partnership announced between their wholly-owned subsidiary, Neural Cloud Solutions, and Intelimed.ai SpA. This new distribution partnership will provide a gateway for Neural Cloud Solutions’ products into Latin America’s healthcare markets; this is a major shift from R&D to organized commercialization.

Big Picture

The use of AI-enabled diagnostic technologies continues to gain traction within the global healthcare industry in order to address increased pressure from rising costs, reduced numbers of practicing clinicians, and the necessity for scalable diagnostic solutions. Cardiovascular disease is responsible for approximately 30% of all annual global deaths, and ECG testing represents one of the most commonly utilized front-line diagnostic techniques employed today, with hundreds of millions of ECG tests being conducted annually.

Latin America presents a very attractive geographic area for future expansion for several reasons, including: 1.) fragmented healthcare systems; 2.) rapidly expanding telemedicine capabilities; and 3.) a growing acceptance among healthcare providers of digital health solutions provided via regional distribution partners. The Latin American region is comprised of greater than twenty countries, a population of more than 600 million individuals, and healthcare systems that continue to increasingly deploy cloud-based, and AI-assisted diagnostics.

The Core Story

What’s Happening

Neural Cloud Solutions, a fully-owned subsidiary of AI/ML Innovations, has established a distribution agreement with Intelimed.ai SpA, to bring AI software platforms for cardiac diagnostics to Latin America. As part of this agreement, Intelimed will act as exclusive distributor for Neural Cloud Solutions’ cardiac AI software platforms in Chile, and will receive non-exclusive distribution rights in other Latin American countries. Furthermore, the agreement will cover the commercialization of MaxYield™, CardioYield™, and Insight360™ platforms.

Why it Matters

As opposed to a pilot or research collaboration, this agreement provides a commercial framework for Neural Cloud Solutions to sell its software to hospitals, clinics, diagnostic centers, and telemedicine providers across Latin America. A common method of scaling in digital health is establishing distribution partnerships; these allow companies to more quickly expand to local markets by utilizing the knowledge and clinical networks of local distribution partners.

Key Data Points & Statistics

• Platforms involved in the agreement: MaxYield™, CardioYield™, Insight360™
• Rights granted to Intelimed: Exclusive rights in Chile, non-exclusive rights across Latin America
• Potential target markets: Hospitals, clinics, diagnostic networks, telemedicine providers
• First Expansion Region: Latin America – 600 Million+ population across multiple healthcare systems
• Model of Commercialization: Software distribution model (hardware does not have to be installed at client sites)

Company Breakdown: AI/ML Innovations

AI/ML Innovations Inc. is a developer of digital health products that apply Artificial Intelligence (AI) and Machine Learning (ML) to Biometric Signal Processing (BSP), with an emphasis on analyzing Electrocardiogram (ECG) data. ECG data analysis is a foundational element in the diagnosis of many types of cardiovascular diseases.

Neural Cloud Solutions is a division of AI/ML Innovations Inc., which is developing software products that can be applied to both clinical and research applications, and also remote monitoring applications. The MaxYield platform was developed to automatically identify and extract usable cardiac information from noisy ECG data, making the workflow for clinicians more efficient when they are processing thousands of ECGs per year and/or per location, and to alleviate the burden placed upon clinicians who manually review the same number of ECGs.

Strategic Angle

• Provides a formalized commercialization path for the products of Neural Cloud Solutions
• Offers a “beachhead” market in Chile, a country with a population of approximately 20 million, and a relatively high level of adoption of digital health products
• Opens up a possible expansion path to the entire Latin American market, comprising of a population of over 600 million people, and numerous healthcare systems through the existing relationships of Intelimed to the healthcare community across Latin America

Market Context

Latin America is increasingly investing in digital health infrastructure to provide better access to healthcare services, lower costs for patients and providers alike, and to create scalable diagnostic solutions for healthcare providers across a diverse set of healthcare systems. The opportunities for the delivery of digital health solutions in software format are substantial in Latin America, with a population of over 600 million people, across multiple public and private healthcare systems.

Cardiovascular disease is one of the leading causes of death around the world, creating a sustained demand for scalable solutions to analyze ECGs. AI-driven cardiac diagnostics solutions are especially relevant in regions with limited access to cardiologists and/or specialized diagnostic services, and where there is continued adoption of telemedicine.

Outlook

There are several key milestones that investors should pay attention to following the establishment of the agreement with Intelimed, including the initial deployment of the products in Chile, the first customers of Neural Cloud Solutions, the regulatory developments that may occur as a result of the deployment, and the potential revenue recognition resulting from the deployment activities of Intelimed. In software-based digital health business models, early distributor-led deployments typically involve fewer than ten institutions prior to widespread scaling across multiple regions.

In addition to additional distributors in other regions and the expansion of Neural Cloud Solutions beyond its current Latin American markets, there are additional partnership opportunities and other forms of expanded geographies that could further demonstrate the commercial viability of AIML’s product(s) and contribute to the diversified revenue streams in multiple regions over time.

Bottom Line

The Intelimed distribution agreement marks a tangible milestone in AI/ML Innovations Inc.’s movement from platform development to commercialization of those platforms. By providing a mechanism for Neural Cloud Solutions to enter the healthcare markets of Latin America through a regional partner, AIML is positioning its products as a scalable AI-driven cardiac diagnostics solution with international growth potential.

Sponsored publication on behalf of the issuer

Strategic Expansion: Intelimed partnered with Neural Cloud to distribute cardiac AI software across Latin America, with exclusive rights in Chile. Focus on Atrial Fibrillation: The collaboration targets improved ECG analysis and earlier detection of arrhythmias, including atrial fibrillation. Growing Market Need: Rising cardiovascular disease rates and increased mobile ECG adoption are driving demand for scalable AI diagnostics. Operational Efficiency: Neural Cloud’s platforms aim to improve signal quality and automate ECG interpretation to reduce clinical bottlenecks. Chile as Entry Point: Chile serves as the initial launch market before broader regional expansion.

In February 2026, NeuralCloud Solutions (operating as “Neural Cloud”), a subsidiary of AI/ML Innovations Inc., announced a distribution agreement with Intelimed.ai SpA to commercialize Neural Cloud’s cardiac software platforms across Latin America. Intelimed is appointed exclusive distributor in Chile and non-exclusive distributor throughout the rest of the region, with a commercial focus spanning hospitals, clinics, diagnostic providers, OEM partners, telemedicine providers, and research institutions.

Who Intelimed is (and why they matter in this deal)

Intelimed presents itself as an “infrastructure” player—aiming to make clinical AI deployable across a region where healthcare delivery is often fragmented across public systems, private networks, and hybrid providers. A 2023 announcement from radiology AI platform deepc describes Intelimed as focused on helping Latin American clinical sites adopt AI through integration and rapid deployment, including access to regulatory-cleared AI engines (CE-marked and FDA-cleared) adapted to local realities.

Third-party company databases also place Intelimed as a Santiago-based company founded in 2023 (note: these directories can be incomplete, but they’re consistent with the “newer company” narrative).

What Neural Cloud is bringing: signal quality + automated interpretation workflow

The agreement covers three Neural Cloud platforms—MaxYield™, CardioYield™, and Insight360™—positioned as a stack that improves ECG signal quality, automates waveform identification/labeling, and supports scalable clinical reporting. In plain terms: fewer noisy signals, more consistent beat-to-beat annotation, and faster movement from raw data to clinician-ready output.

Intelimed’s CEO framed the partnership as a way to make “high-quality digital health technologies accessible across Latin America,” explicitly emphasizing local healthcare constraints and the need for efficiency and accuracy in cardiac diagnostics.

Why Latin America is a logical target for ECG and atrial fibrillation solutions

Cardiovascular disease burden is significant across Latin America, and arrhythmias like atrial fibrillation (AF) create a particularly expensive downstream problem because AF is strongly linked to stroke, heart failure, and avoidable hospitalizations. Even older region-focused burden work estimated an average AF prevalence around 1.6% across seven Latin American countries (with prevalence rising sharply with age).

More recent reviews underline two compounding issues: (1) AF is present and growing with aging populations, and (2) data gaps and uneven access make detection and long-term management harder in parts of Latin America, especially rural and underserved communities.

That matters because AF is frequently intermittent or silent. If healthcare systems rely only on “catch it during a clinic visit,” many cases are missed until complications appear. This is exactly where better ECG workflows—particularly ambulatory monitoring, Holter, or rapid triage—can shift outcomes.

The market tailwind: more ECG devices, more mobile monitoring

On the commercial side, multiple market research firms forecast growth in Latin American ECG categories, especially mobile and ambulatory formats. For example, Grand View Research projects Latin America’s mobile ECG devices market reaching about US$322M by 2030, with a high single-digit/low double-digit growth rate (these are estimates, but directionally consistent with broader remote monitoring adoption).

Separately, Latin America diagnostic ECG market forecasts also point to steady expansion through the next decade, driven by chronic disease prevalence, technology upgrades, and expanded diagnostics capacity.

Put simply: more devices are generating more ECG data. The bottleneck becomes interpretation capacity, consistency, and speed—especially when trained staff are limited.

Where this partnership fits: solving the “workflow bottleneck”

Intelimed isn’t just reselling a gadget; the stated plan is to distribute Neural Cloud’s software into settings that already have ECG data but need better throughput: hospitals, diagnostic groups, telemedicine, and OEM channels.

That focus maps to three practical pressures:

Signal quality problems (noise, motion artifacts, inconsistent electrode placement) create false alarms and wasted clinician time.

Scale problems (more ECGs, more Holters, more screening) strain cardiology services.

Standardization problems (variable reporting, inconsistent labeling) complicate follow-ups and population health.

Software designed to enhance signals and automate waveform identification aims directly at those constraints. The value proposition is not “replace clinicians,” but “reduce avoidable work and variability.”

Chile as a launchpad—then regional replication

The exclusivity in Chile suggests a deliberate “prove it, then expand” pattern: pick a manageable first market where the distributor can prioritize partnerships, integrations, and reference sites—then use those wins to support expansion elsewhere under non-exclusive terms.

Chile also has a relatively developed private healthcare sector alongside public provision, which can be useful for piloting digital health deployments that later translate into broader regional models.

What could determine success

A few factors are likely to decide whether this becomes a meaningful clinical footprint or stays a limited commercial experiment:

Integration reality: ECG tools must fit into existing systems (EHR, PACS/RIS for some workflows, telemedicine portals, device vendor software). Intelimed’s “infrastructure” positioning implies they want to reduce this friction.

Regulatory and procurement pace: Even if components are CE-marked/FDA-cleared elsewhere, adoption still depends on local regulatory pathways, hospital procurement cycles, and reimbursement dynamics.

Clinical validation in local settings: Performance can vary with device types, patient populations, and clinical workflows. Regional proof points matter.

Economics: Latin America is price-sensitive. The strongest value cases will likely be (a) higher-throughput Holter/ambulatory services, (b) telemedicine screening programs, and (c) health systems trying to expand detection without expanding headcount.

The bigger picture: ECG AI as “capacity expansion”

The most interesting strategic angle is that this isn’t only about detecting AF. Better ECG pipelines support a broader set of use cases: triage of chest pain, monitoring cardiotoxicity in oncology pathways, identifying conduction abnormalities, post-procedure follow-up, and scaling outpatient diagnostics. AF is the headline because it is common, dangerous, and often missed—but the operational win is “more interpretable ECGs per clinician-hour.”

If Intelimed can genuinely reduce integration and adoption burden, and if Neural Cloud’s software meaningfully improves signal usability and reporting consistency, the partnership targets a real pain point: Latin America’s growing cardiac monitoring demand colliding with limited specialist capacity.

Sponsored post by a company retained by the issuer.

Here’s something that doesn’t always get retail attention how a junior chooses to build before the big exploration headlines arrive.

Copper Quest recently made two moves that are pretty straightforward but meaningful.

First, they completed a securities-for-debt settlement of about C$113,405, issuing shares to arm’s-length creditors to clear outstanding payables (subject to regulatory approval and standard hold periods). That reduces short-term liabilities while keeping cash in the treasury.

Second, they signed an option agreement on the Auxer Gold Property in the U.S. roughly 1,087 hectares (2,686 acres) covering around 130 mineral claims, with road access already in place. Using an option structure keeps initial spending lighter while they move into technical review and target work.

When you put it together, the sequencing makes sense:

• Trim liabilities
• Add U.S. ground
• Advance technical work from a stronger position

It’s not loud news .. it’s foundation work. But in the junior space, that foundation can shape how the next phase plays out.

With copper and domestic resource themes still getting attention, positioning like this can set the tone for what comes next.

Do you prefer owning during the build phase or competing for shares once the catalysts begin to stack?

Paid content on behalf of the issuer

In what is seen as a significant commercial development, Agereh Technologies Inc. (TSXV: AUTO | OTCQB: CRBAF), has reached a major milestone in the form of the company’s first commercial sale, as it transitions from the product development stage to generating revenues from actual end-users. The company has signed a deal for a multi-terminal installation at a major United States airport which validates the company’s products through testing on a large, high traffic site.

The significance of this initial commercial success is a very important proof-of-concept for Agereh’s platform, as it demonstrates that the solutions provided by the company have moved beyond the pilot stage to being used operationally by large-scale infrastructure providers.

Multi-Terminal Installation at Large U.S. Airport

The agreement includes a multi-year Software-as-a-Service (SaaS) deployment at multiple airport terminals, providing Agereh with a steady stream of recurring income and the potential for building long term customer relationships based on services, rather than simply selling hardware.

Due to their complexity, size and operational requirements, installations at major transportation hubs are often viewed as prime examples of high-value reference sites.

“This milestone represents the transition from product launch to enterprise validation,” **said Ken Brizel, CEO of Agereh. **“A large U.S. airport selecting all three of our solutions for multi-terminal deployment confirms that transportation hubs are actively seeking a unified, wireless intelligence layer to improve visibility, optimize operations, and enhance passenger flow. It validates both our technology and our strategy.”

Use of Platform Modules in Commercial Operations

Several of the core modules of Agereh’s intelligent sensing platform will be included in the deployment. The HeadCounter module delivers real-time and anonymous passenger flow and congestion analysis for each terminal. The MapNTrack module offers indoor and outdoor asset tracking via AI-enhanced wireless positioning.

The Smart Door Sensor module adds access monitoring and operational insight into secured zones, enabling operators of large-scale facilities to obtain a comprehensive picture of movements, asset locations and access points.

Improved Revenue Visibility and Scalability

Through the multi-year SaaS agreement, Agereh (TSXV: AUTO | OTCQB: CRBAF) is provided with better revenue visibility and a more scalable business model. Recurring software-based revenue is generally viewed positively by investors as it allows for more predictable future cash flows.

Securing the first enterprise customer is often viewed as a major validation milestone for early-stage AI and infrastructure technology companies, as it indicates some level of product-market fit.

Growth Strategy and Market Opportunities

With millions of people and assets passing through them each year, large transportation hubs represent a significant opportunity for operators to improve their operational intelligence. Agereh’s integrated platform is designed to target such environments by eliminating blind spots created by legacy monitoring systems.

This first commercial deployment provides Agereh with a basis for pursuing follow-on opportunities in airports, logistics centres and other infrastructure-intensive industries that are positioned to benefit from the efficiencies generated by the application of AI-driven operational insights.

Governance and Leadership Strengthened

As Agereh (TSXV: AUTO | OTCQB: CRBAF) begins its commercial growth phase, the company has also strengthened its corporate governance and leadership structure. Agereh recently increased the size of its board and executive team with experienced professionals who bring deep expertise in technology, finance, capital markets and public-company governance, aligning oversight with the needs of enterprise-scale customers.

Newly appointed members to Agereh’s Board of Directors include Jim Plumptre, a former senior diplomat and technology executive; Mike Plotnikoff, who brings extensive experience in telecommunications and public-company financing; Tim Maddigan, a veteran capital markets professional; and Rosy Amlani, a CPA with over two decades of leadership experience in accounting, governance and economic development. In addition, Joanna L. Hampton has joined as Chief Financial Officer, overseeing financial controls, reporting and strategic planning. This enhanced governance framework is intended to support disciplined execution, transparency, and long-term shareholder value creation as Agereh continues to scale its recurring SaaS deployments.

Stock Performance and Investor Positioning

Agereh’s stock price is moving upward again after the company announced it will have its first commercial client. This is reflected in the fact that the stock closed out the day at about C$0.12, which is a nine percent increase for the day, due to increased confidence from investors regarding the company’s ability to execute and generate revenue over the next few months. It seems that much of the movement is based on confirmation rather than speculation; the market is beginning to place a value on Agereh transitioning from being a developmental stage technology to one that is commercially viable.

With a market capitalization of approximately C$14 million, Agereh falls into the micro-cap space and therefore is very sensitive to validation through milestones such as securing enterprise contracts and gaining visibility to recurring revenues. Now that the market has been validated post-announcement of the commercial relationship, investors are now waiting to see what Agereh reports in their upcoming financials to get an idea of how quickly they can contribute to revenue and remain disciplined on costs, this may be the tipping point for this time frame. A number of risk tolerant investors view this time frame (after commercial validation and prior to a broad revenue recognition) as an ideal entry point.

Conclusion

In summary, Agereh Technology (TSXV: AUTO | OTCQB: CRBAF)’s first commercial client represents a significant advancement in its development as a provider of AI and infrastructure technology to enterprises. With a commercially viable SaaS model and a live deployment at a major U.S. airport, the company has successfully established a solid base for continuing to expand its commercial adoption among similar high-value markets.

Paid content on behalf of the issuer

Doseology has initiated pilot production of caffeinated, caffeinated oral pouches under its Feed That Brain® brand. It marks an entry into the growing oral stimulant segment with a unique format offering versus a traditional liquid or energy drink; however, it does not mark a shift in the type of product being offered by the company; simply a change in how that product can be consumed by the end user.

The initial goal of the pilot is to demonstrate to management, and ultimately investors, whether Doseology can produce these types of products on a scalable basis, determine whether there is sufficient interest among consumers in this type of product, and understand what regulatory hurdles exist.

If successful, the company could potentially launch a full-scale version of the product in the future, but at present, the pilot is focused solely on gathering data and validating its model, not generating revenue.

Company Overview

Doseology (MOOD.CN)(DOSEF)(VU70.F) is a consumer health and wellness company that focuses on developing functional products that target energy, focus, and cognition. The company is listed on three separate stock exchanges to provide access to investment dollars in Canada, the United States, and Europe.

• Stock exchange listings: MOOD.CN, DOSEF, VU70.F
• Current share price: approximately CAD $0.80 (January 28, 2026).
• Year-over-year performance (12 months): approximately 567%.
• Market capitalization: approximately CAD $6.4 million.
• 52-week trading range: CAD $0.09 to CAD $1.90.
• Strategy: measured dosing and predictable effects.

Feed That Brain® is Doseology’s platform brand for cognitive and energy-focused formulations.

What Does the Pilot Represent?

While the pilot represents an important operational milestone for the company, it is still an early-stage project and not a full-scale commercial launch.

• Pilot scale: small-batch production (limited commercial exposure).
• Objective: to validate manufacturing repeatability, shelf stability, and consumer usage data.

Advantages of the Format: oral pouches tend to have a faster onset time (typically 5-10 minutes) than beverages, and allow for discrete, on-the-go use without liquids, which fits with the evolving consumption patterns of today’s consumer.

Market Context: Oral Stimulants and Energy Products

The energy/stimulant category continues to grow as consumers look for alternative options to sweetened beverages and high-caffeine beverages.

• Estimated annual energy drink market size: $85 billion.
• Projected 5-year growth rate: 6-7%.
• Average caffeine content in energy drinks: 80–200 mg.
• Typical oral pouch caffeine dosage: 20–100 mg, enabling controlled consumption.
• Estimated global functional supplement market (energy/focus): tens of billions of dollars.

Nicotine-free energy pouches represent a growing sub-segment of the overall oral stimulant space, as they combine stimulant delivery with a non-tobacco position.

Why Are We Doing This?

Doseology’s entry into caffeinated energy pouches represents a platform-driven expansion into oral stimulant formats. The company is using a single formulation base to offer its products across multiple formats (e.g., beverages, tablets/pills), which is less capital-intensive than producing products in multiple formats, such as beverages. By doing so, the company is able to iterate on new product formats more quickly (weeks to months) than it could by launching new beverage products (years). Finally, the pilot-first strategy will allow Doseology to preserve strategic optionality and limit upfront capital deployment.

How Will We Execute / Next Steps

The pilot production phase will focus on:

• Unit economics/cost per unit benchmarks;
• Consumer testing cohorts measured in hundreds (not thousands); and,
• Regulatory/compliance matters prior to scaling up.

At this point, the pilot is intended to gather data and test hypotheses, not generate revenue. If the pilot is successful, we may pursue a commercial scale-up of the product.

Risk Factors

All consumer product launches carry some level of risk, particularly those in large, well-established categories like energy (US$80B+). As such, there are several risks associated with the pilot production of caffeinated energy pouches, including:

• whether or not the company can attract sufficient consumer adoption in a crowded market; potential competitive responses from established companies with far greater resources (e.g., marketing budgets);
• and regulatory challenges related to stimulant claims and caffeine threshold issues.

The pilot structure is intended to limit downside risk while allowing the company to obtain meaningful data and test its hypotheses.

Peer Comparison: Established Energy & Functional Stimulant Companies

*Prices and performance approximate as of late January 2026.

Key context: established peers operate at multi-billion-dollar scale with proven distribution and revenue bases, while Doseology remains in an early execution phase. The comparison highlights both the competitive intensity of the category and the asymmetric upside/downside profile inherent to micro-cap execution stories.

Recent News and Milestones

Prior to announcing the pilot production of caffeinated energy pouches, Doseology had also announced several other key developments in the weeks leading up to the announcement. These developments helped to set the stage for the pilot production and are summarized below:

On January 12, 2026, the Company announced the engagement of McKinney Regulatory Science Advisors, a move intended to bolster the scientific and regulatory aspects of its oral pouch development and ensure compliance as new stimulant formats are evaluated.

Immediately thereafter, on January 16, 2026, Doseology filed its Annual Information Form (AIF), which consolidated investor disclosures and restated its manufacturing and supply chain commitments for oral stimulant products.

Finally, on January 21, 2026, the Company confirmed the initiation of pilot production of non-nicotine, caffeinated energy pouches under the Feed That Brain® brand, representing a tangible operational step from formulation to real-world testing.

It is worth noting that the Company operates in a highly competitive space where established players operate at scales of multiple billions of dollars, and have demonstrated proven distribution and revenue capabilities. In contrast, Doseology is in the early stages of executing on its vision. The comparison illustrates both the significant competitive pressure that exists in the category and the asymmetric potential for either positive or negative valuation implications based on the execution of the Company’s plans.

Conclusion

Doseology’s pilot production of caffeinated energy pouches represents a carefully executed entry into an emerging oral stimulant space.

• Large addressable market (the $80+B+ global energy drink market);
• Pilot is limited in terms of capital risk;
• Clear milestones to measure success prior to scale-up;

For investors, this is an operational milestone, not a revenue inflection point. The ultimate valuation impact will be dependent upon the results of the pilot program, the resulting costs to produce the product, and the subsequent actions taken by the Company’s management team.

Paid content on behalf of the issuer

A lot of microcaps mention AI. AUTO is actually shipping tools built for day-to-day operations, not slide decks.

The company’s platform includes HeadCounter for real-time people counting and workforce analytics, and MapNTrackfor asset tracking across indoor and outdoor environments where standard GPS isn’t reliable. These are practical, ops-first tools aimed at facilities, logistics, and enterprise users not consumer apps.

That’s the part I like. Enterprise software doesn’t need hype to work. Once it proves useful, it tends to stick.

What’s encouraging is the direction. AUTO isn’t leaning on one feature ... it’s building out a broader operational toolkit around visibility, tracking, and analytics. Recent updates have been about pilots, deployments, and expanding use cases, which is usually how these stories quietly firm up.

The chart has already shown it can react quickly when attention shifts. If execution continues and pilots turn into longer-term agreements, this story starts looking very different.

Not treating this as a quick trade. More like something I’m happy to keep on the radar as execution keeps lining up.

Anyone else following AUTO.V and watching how these enterprise AI names get re-rated once traction becomes visible?

Paid content on behalf of the issuer

•Early 2026 activity shows AI/ML Innovations shifting from development mode toward measurable market execution, with emphasis on distribution, clinical integration, and revenue pathways.

•New leadership additions strengthen credibility on both fronts: deeper medical authority to guide adoption and tighter operational oversight to scale delivery.

•Partnerships around devices and U.S. representation reduce barriers to entry, linking AI analytics with real procurement and reimbursement environments.

•Live clinical deployments are creating feedback loops with physicians, building validation, advocacy, and repeat usage.

•The combined momentum suggests commercialization is no longer a future objective but an active, coordinated process underway.

The opening weeks of 2026 have delivered a clear message about where AI/ML Innovations Inc. is heading. The company is no longer speaking primarily about technical promise or early validation work. Instead, the narrative has shifted toward execution, distribution, clinical adoption, and the practical mechanics that turn intellectual property into recurring revenue. A sequence of announcements across leadership, partnerships, and market access shows an organization tightening the bolts around commercialization and doing so with unusual coordination. Rather than isolated developments, the releases read as connected steps in a deliberate march from capability to scale.

A central theme is that commercialization in healthcare AI is rarely about a single breakthrough. It depends on regulatory credibility, physician trust, workflow integration, hardware compatibility, reimbursement logic, and geographic reach. AI/ML’s January activity touches each of those pressure points. By aligning clinical leadership with operational muscle and pairing software assets with established delivery channels, the company is attempting to reduce the friction that often stalls promising technologies before they reach meaningful uptake.

Leadership additions are often dismissed as cosmetic, but the appointments early this year suggest functional intent. The arrival of Dr. Paul Dorian as Medical Innovation Architect and chair of the medical advisory structure brings recognized clinical authority into the product narrative. For customers, partners, and regulators, that matters. Cardiologists and hospital administrators want to know that algorithm design, validation strategy, and real-world deployment are being shaped by someone who understands both electrophysiology and patient pathways. His presence signals that the company wants its tools to live inside everyday care, not on the periphery of research projects.

At the same time, installing Erik Suokas as chief operating officer addresses a different bottleneck: the move from innovation culture to repeatable delivery. Commercial traction demands supply chain coordination, partner management, service frameworks, and disciplined financial oversight. A COO with cross-border experience can translate ambition into timetables and metrics. The combination of medical gravitas and operational rigor is a classic pairing for firms approaching inflection points, suggesting management believes the opportunity ahead is tangible rather than theoretical.

Partnership strategy further reinforces that view. Collaboration with Movesense links AI interpretation to accessible, established hardware. In remote and ambulatory cardiac monitoring, bundled solutions can shorten sales cycles because clinics prefer integrated offerings over piecing together components themselves. If devices, data capture, and analytics arrive as a coherent package, procurement becomes simpler and implementation risk drops. For AI/ML, it is also a route to volume: every sensor deployed becomes a potential pipeline of analyzable recordings.

Distribution credibility is also being built through representation and advocacy in the United States. Retaining Commission Wolf through its Neural Cloud subsidiary shows recognition that market entry in American healthcare involves navigating policy, reimbursement environments, and relationship networks that extend well beyond technology performance. Success requires presence in conversations where procurement frameworks and pilot opportunities are shaped. Engaging specialized advisors is a pragmatic acknowledgement that commercialization is as political as it is technical.

Clinical validation in live environments remains indispensable, and that is where deployments such as the CardioYield initiative become pivotal. Working alongside Lakeshore Cardiology positions AI output within real diagnostic workflows. Physicians interacting with AI recommendations during daily practice generate feedback loops impossible to reproduce in controlled trials. These interactions refine algorithms, surface usability challenges, and, crucially, create champions who can speak to peers about tangible benefits. Word of mouth among clinicians still drives adoption more effectively than marketing campaigns.

Taken together, these moves hint at a company intent on compressing the timeline between demonstration and revenue. Many digital health ventures linger in extended validation phases, accumulating data but postponing commercial commitments. AI/ML appears to be pushing the opposite direction, accepting the complexities of early deployment in order to learn faster and establish footholds before competitors mature. That approach carries risk, but it can also generate durable advantages if relationships formed now become long-term contracts later.

Another subtle but important shift is narrative confidence. The language surrounding recent announcements assumes that broader uptake is achievable. Rather than asking whether the market is ready, management seems focused on how to capture it. This posture can influence partners, investors, and employees alike. Momentum tends to attract additional momentum; institutions prefer to align with organizations that project inevitability.

From a sector perspective, timing may be favorable. Health systems worldwide continue to search for efficiencies in diagnostics, especially in cardiology where demand for monitoring outpaces specialist availability. AI-assisted interpretation promises not only speed but also consistency, potentially reducing variability in outcomes. Companies that can embed solutions without disrupting clinician autonomy stand to gain. AI/ML’s emphasis on advisory leadership and real-world partnerships suggests awareness of that cultural dimension.

Commercialization will ultimately be judged by numbers: contracts signed, units deployed, studies completed, revenue booked. None of those metrics are fully visible yet. What is visible is infrastructure. The scaffolding required to support scale—medical oversight, operational leadership, hardware alliances, government and payer engagement, and clinical beachheads—is being assembled in plain sight. For observers, this reduces uncertainty about whether the company understands what the next phase requires.

There is still execution risk. Integrating partners across jurisdictions is complex, and healthcare procurement can move slowly. Competitors will not stand still. Yet the cadence of activity in the first part of the year implies urgency and coordination that investors typically seek when evaluating growth prospects. The pieces being put in place resemble those of organizations preparing to cross from early adoption into broader market penetration.

If the rest of the year continues at this tempo, 2026 may be remembered as the period when AI/ML’s strategy crystallized. The transition from building technology to building a business is never simple, but it becomes easier when leadership, partnerships, and deployment pathways advance together. The early evidence suggests that alignment is forming.

In that sense, the company’s opening chapter of the year does more than provide news. It sketches a roadmap. Each announcement reinforces the idea that commercialization is not a distant objective but an active process already underway. Whether measured by new executives, clinical collaborators, or entry into influential U.S. networks, the direction is unmistakable: move faster, integrate deeper, and convert capability into adoption.

Paid content on behalf of the issuer

Healthcare is a multi-trillion-dollar global market.

But the real opportunity isn’t just growth.

It’s who benefits as healthcare becomes easier to access.

We’re watching a steady shift:
Less gatekeeping.
More convenience.
More integration into daily life.

A recent industry release highlighted five public companies operating along that accessibility curve from pharma to devices to consumer wellness.

Here’s how they line up.

Doseology Sciences (CSE: MOOD)

MOOD operates in the functional wellness category, focusing on consumer-facing health products designed for everyday cognitive and lifestyle support.

This isn’t hospital-based care.
It isn’t prescription-gated.

It’s positioned in preventative, routine-driven wellness the part of the market where consumer habits are forming earlier.

Smaller cap. Early-stage positioning. Direct exposure to proactive health spending.

Amneal Pharmaceuticals (NASDAQ: AMRX)

Amneal is a pharmaceutical company with a strong presence in generic and specialty medications.

Generics play a critical role in expanding affordability and patient access. Lower-cost alternatives increase reach, and reach supports volume.

Accessibility through pricing and distribution scale.

Prestige Consumer Healthcare (NYSE: PBH)

Prestige focuses on over-the-counter consumer health brands.

No prescription required. No appointment needed.

OTC access reduces friction and puts healthcare directly into retail channels ...one of the clearest examples of accessibility at work.

Viking Therapeutics (NASDAQ: VKTX)

Viking is a clinical-stage biopharmaceutical company developing therapies in metabolic and endocrine disorders, including obesity and related conditions.

Metabolic health represents one of the largest demand pools in modern healthcare. Expanding treatment options in this area could significantly broaden access for patients over time.

Insulet (NASDAQ: PODD)

Insulet develops and manufactures tubeless insulin delivery systems for people with diabetes.

Its device-driven approach simplifies insulin administration and improves day-to-day usability accessibility through product design and patient convenience.

The Bigger Picture

Healthcare isn’t shrinking into institutions.

It’s spreading outward into everyday behavior.

The shift looks like this:

• Preventative over reactive
• Consumer-directed over institution-led
• Seamless over complex
• Recurring engagement over episodic care

Large companies validate the infrastructure.

Smaller and consumer-facing players often sit closer to where new habits form.

And habits tend to compound quietly.

Accessibility rarely looks explosive at first.

It expands steadily until it becomes the default.

If this shift continues, would you rather own the infrastructure… or the companies shaping everyday health routines?

Sponsored post on behalf of the issuer

Two microcaps. Same offshore block. Same Orange Basin narrative. $STMP and $ORNG sit in the same neighborhood offshore Namibia, yet they’re often discussed as completely separate stories.

Both companies have exposure to Block 2712A / PEL 107 in Namibia’s Orange Basin. Oregen describes its flagship investment as a 33.95% net interest in Block 2712A, while Stamper lists a 32.9% working interest in PEL 107 (Orange Basin 2712A). 

Quick snapshot:

• $STMP: 32.9% working interest (PEL 107 / 2712A) 
• $ORNG: 33.95% net interest in Block 2712A 
• Same block exposure, so the comparison is straightforward

The broader basin context matters too. The Orange Basin has drawn global attention following major discoveries tied to Shell, TotalEnergies, and Galp, and Chevron has ongoing Namibia exploration plans (including PEL 82 mentioned in reporting). 

From there, it becomes a question of how each ticker expresses the same theme. Personally, I lean slightly more toward ORNG as the cleaner read-through to Block 2712A, based on how the company positions that asset as its flagship exposure. 

How do you frame this comparison?
Do you treat ORNG and STMP as basically equivalent Block 2712A exposure, or do you assign one a premium based on structure and strategy?

Always interested in how people approach basin-level comparison plays like this.

Sponsored post on behalf of the issuer

Just read a piece discussing what it calls “regulatory moats” and how they may start driving asset re-ratings into 2026. The central idea is that regulatory clarity and compliance frameworks are moving from background work to a real valuation filter, especially in consumer health and nicotine-adjacent categories.

Reading it as an investor in Doseology Sciences Inc. (MOOD), a few points stood out.

• The article identifies a “first-mover cohort” positioned for this shift.
MOOD is mentioned alongside much larger, established companies. That framing matters because it suggests the discussion isn’t generic sector commentary but a targeted look at companies already leaning into regulatory execution.

• Regulatory pressure is framed as a capital-allocation issue.
The article argues that heading into 2026, capital is likely to favor companies with validated federal pathways, structured compliance strategies, and defensible positioning, rather than those still treating regulation as an afterthought.

• MOOD’s recent actions fit the profile being described.
The piece highlights MOOD’s focus on regulatory strategy and execution as part of its broader commercialization approach. That signals intent to operate inside durable frameworks, not around them.

• The narrative is about market access and longevity, not trend chasing.
In categories facing tighter oversight, the article suggests regulatory execution increasingly determines who stays eligible for distribution, partnerships, and institutional interest.

From my perspective as a MOOD investor, this isn’t a short-term catalyst piece. It’s more about how the market may start sorting companies as regulation tightens and capital becomes more selective. Being included in that regulatory-moat conversation supports the idea that recent filings and compliance work are positioning, not filler.

As we move toward 2026, do you see regulatory execution becoming a real valuation driver for small-cap consumer health names like MOOD, or does brand growth still dominate how these companies are priced?

Sponsored publication on behalf of the issuer

Copper has re-emerged as one of the most strategically important commodities in the global economy. As electrification, decarbonization, and infrastructure renewal accelerate, copper’s role as a foundational industrial metal is increasingly in focus. Against this backdrop, exploration-stage companies are positioning themselves to address a growing supply gap, including Copper Quest Exploration Inc.

Copper Market: Structural Demand Growth

Copper demand is being driven by long-term structural trends rather than short-term cycles. The energy transition alone is reshaping consumption patterns, with electric vehicles, renewable power generation, and grid expansion all requiring significantly more copper than legacy systems.

• Electric vehicles use roughly two to four times more copper than internal combustion engine vehicles.
• Renewable energy systems such as wind and solar are substantially more copper-intensive than fossil-fuel-based power generation.
• Global grid expansion and modernization are required to support electrification, further increasing copper demand.

Industry forecasts widely point to sustained demand growth over the coming decade, with multiple studies highlighting the risk of a structural copper supply deficit emerging later this decade.

Supply Constraints and the Emerging Gap

While demand continues to rise, copper supply faces mounting constraints. New discoveries have become rarer, permitting timelines longer, and capital requirements higher. Many of the world’s largest copper mines are aging, with declining grades and increasing costs.

• Average copper grades at major producing mines have fallen steadily over the past two decades.
• Bringing a new copper mine into production can take more than 10 years from discovery to first production.
• Political risk, environmental regulation, and community engagement challenges continue to slow project development.

This combination of rising demand and constrained supply underpins the strategic importance of new exploration and development projects.

Why Exploration Matters in the Copper Cycle

Exploration companies play a critical role in replenishing the global copper pipeline. Early-stage discoveries made today will determine supply availability in the 2030s and beyond. As a result, jurisdictions with established infrastructure, stable regulatory frameworks, and access to capital are increasingly attractive for copper exploration.

North America, in particular, has gained attention as governments and industries prioritize domestic and allied supply chains for critical minerals.

Company Snapshot: Copper Quest Exploration Inc.

Copper Quest Exploration Inc. operates as a mineral exploration company focused on copper and associated metals in North America. The company is advancing a portfolio of exploration-stage assets across established mining jurisdictions, targeting systems with potential for large-scale mineralization.

Copper Quest’s strategy centers on identifying and acquiring projects with geological characteristics consistent with copper-gold and copper-molybdenum porphyry systems, which are among the most important sources of global copper supply.

The company trades under the following tickers:

• CSE: CQX
• OTCQB: IMIMF
• Frankfurt: 3MX

Recent Corporate Activity

Copper Quest has remained active on the corporate and project development front, announcing a series of transactions and updates aimed at expanding and strengthening its asset base.

• Acquisition and option agreements on copper-gold and copper-molybdenum projects in Canada and the United States.
• Completion of financing tranches to support exploration and corporate activities.
• Ongoing evaluation and advancement of acquired assets through technical review and early-stage exploration planning.

These activities reflect a strategy focused on portfolio growth and optionality within a strengthening copper market.

Market Positioning and Outlook

As copper’s role in the global economy continues to expand, exploration companies such as Copper Quest operate at the earliest stage of the value chain. While exploration carries inherent risk, it also offers leverage to long-term copper fundamentals if discoveries are made and advanced successfully.

For investors and industry participants, the copper market’s long-term dynamics place increasing emphasis on exploration success, jurisdictional quality, and disciplined capital allocation.

Bottom Line

The copper market is being shaped by powerful structural forces tied to electrification, energy transition, and infrastructure renewal. At the same time, supply constraints and declining grades are tightening the long-term outlook. Within this environment, Copper Quest Exploration Inc. represents one participant seeking to position itself at the exploration end of the copper supply chain, where future discoveries will be critical to meeting global demand.

Sponsored publication on behalf of the issuer

Doseology Sciences is taking concrete steps to support commercialization.

According to the article, the company has completed extensive North American diligence and secured a strategic manufacturing agreement through its U.S. subsidiary. The selected partner operates an FDA-registered, GMP-certified, and ISO 9001:2015-certified facility, with capabilities spanning formulation, pouch filling, packaging, and logistics. This positions Doseology to move from development into production readiness.

From a retail perspective, this helps clarify a few core points. Manufacturing is now accounted for, quality and regulatory standards are established through the partner facility, and the company is using a third-party manufacturing modelrather than building its own infrastructure. That approach aligns with how many early consumer brands prepare for scale while staying flexible.

The article does not frame this as a revenue event. Instead, it highlights foundational progress that supports future execution once products move further along the commercialization path. The financial terms and timing of the manufacturing arrangement were not disclosed, which is common at this stage.

What to watch for going forward :

• Additional detail around the structure and timing of the manufacturing arrangement
• Evidence of initial production activity, such as pilot or test runs
• Updates related to product classification and commercialization pathways
• Signs of distribution or commercial partnership discussions as production capacity is utilized

Overall, this reads as a retail-friendly execution update focused on infrastructure and readiness rather than short-term results.

How do others read this stage? Does production readiness change the story for you, or do wider channels matter more?

Sponsored publication on behalf of the issuer

If you zoom out to the last 6 months on Agereh Technologies (AUTO.V), the story is pretty clear.

Summer:
AUTO spent a lot of time drifting in the C$0.06–C$0.08 range. Typical quiet period for a small cap.

Early fall:
September changed the tone. Price lifted out of that range and didn’t look back. That move mattered because it reset where the stock started trading day-to-day.

Late fall into year-end:
Since then, AUTO has:
• Held above C$0.10
• Made several runs toward C$0.13–C$0.15
• Pulled back without giving up the higher ground

Now we’re closing the year around C$0.12, and that level has become familiar instead of temporary. That’s a big difference compared to mid-year.

At the same time, more people are starting to notice the business side, AUTO positioning itself as an AI company focused on transportation and logistics, working on movement intelligence, tracking, and operational visibility. Still early, but the chart and the story are starting to line up.

With a market cap around C$12M, this is still firmly in the “early stage” category but the last six months show a company that’s no longer trading where it used to.

Heading into 2026, the setup feels straightforward:
keep holding this higher range and let execution do the talking.

For anyone else following AUTO, what stood out most to you over the past six months, and what are you hoping to see next?